[Cryptococcus meningitis, five years of experience and literature review]

Rev Med Chir Soc Med Nat Iasi. 2008 Jan-Mar;112(1):100-3.
[Article in Romanian]

Abstract

The aim of this study was to determine the distribution and antifungal susceptibility profile of Cryptococcus spp. isolated from patients in northeast Romania.

Material and method: Fungi isolated from blood and cerebrospinal fluid (CSF) cultures were identified by ID32C strips (bioMerieux, France). Susceptibility testing was performed using ATB FUNGUS2 strips (bioMerieux, France).

Results: A total of 20 significant strains have been isolated. Overall, Cryptococcus neoformans was the most frequent isolate (95%). We mention the first Cryptococcus albidus meningitis in Romania (strain with multiple resistance). All cryptococci tested were susceptible to amphotericin B with minimal inhibitory concentration (MIC) =1 microg/mL; 90% strains were susceptible to flucytosine. Resistance to fluconazole and itraconazole was observed in 2 and 1 case, respectively. Most of the patients had an associated infection, tuberculosis in 37.5% cases. Despite appropriate therapy 4 patients died (21%).

Conclusion: First choice induction therapy with amphotericin B plus flucytosine followed by fluconazole is highly recommended since resistance to antifungal agents is still very low.

Publication types

  • Review

MeSH terms

  • Adolescent
  • Adult
  • Amphotericin B / therapeutic use
  • Antifungal Agents / therapeutic use
  • Cryptococcus neoformans / drug effects*
  • Cryptococcus neoformans / isolation & purification
  • Drug Resistance, Fungal
  • Drug Therapy, Combination
  • Female
  • Fluconazole / therapeutic use
  • HIV Infections / complications
  • HIV Infections / drug therapy*
  • HIV Infections / mortality
  • Humans
  • Immunocompromised Host*
  • Itraconazole / therapeutic use
  • Male
  • Meningitis, Cryptococcal / complications
  • Meningitis, Cryptococcal / drug therapy*
  • Meningitis, Cryptococcal / mortality
  • Middle Aged
  • Retrospective Studies
  • Romania / epidemiology
  • Survival Analysis
  • Treatment Outcome
  • Tuberculosis, Pulmonary / complications
  • Tuberculosis, Pulmonary / drug therapy*
  • Tuberculosis, Pulmonary / mortality

Substances

  • Antifungal Agents
  • Itraconazole
  • Amphotericin B
  • Fluconazole